Cargando…
Targeting of elevated cell surface phosphatidylserine with saposin C-dioleoylphosphatidylserine nanodrug as individual or combination therapy for pancreatic cancer
Pancreatic cancer is one of the deadliest of cancers with a five-year survival of roughly 8%. Current therapies are: surgery, radiation and chemotherapy. Surgery is curative only if the cancer is caught very early, which is rare, and the latter two modalities are only marginally effective and have s...
Autores principales: | Davis, Harold W, Kaynak, Ahmet, Vallabhapurapu, Subrahmanya D, Qi, Xiaoyang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204355/ https://www.ncbi.nlm.nih.gov/pubmed/34163572 http://dx.doi.org/10.4251/wjgo.v13.i6.550 |
Ejemplares similares
-
Enhanced phosphatidylserine-selective cancer therapy with irradiation and SapC-DOPS nanovesicles
por: Davis, Harold W., et al.
Publicado: (2019) -
Variation in human cancer cell external phosphatidylserine is regulated by flippase activity and intracellular calcium
por: Vallabhapurapu, Subrahmanya D., et al.
Publicado: (2015) -
SapC–DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents
por: Kaynak, Ahmet, et al.
Publicado: (2021) -
Biotherapy of Brain Tumors with Phosphatidylserine-Targeted Radioiodinated SapC-DOPS Nanovesicles
por: Davis, Harold W., et al.
Publicado: (2020) -
Phosphatidylserine: The Unique Dual-Role Biomarker for Cancer Imaging and Therapy
por: Kaynak, Ahmet, et al.
Publicado: (2022)